The fear of breast cancer—and its link to estrogen use—causes many women to decline or discontinue estrogen replacement therapy. SERMs offer many of the same benefits with fewer risks, broadening the options for protecting long-term health.

BY ANTHONY A. LUCIANO, MD
Although it was initially considered a female sex hormone, estrogen is now recognized as a systemic substance that affects every organ system and appears to be important for both men’s and women’s health. At puberty, elevated circulating estrogen levels transform girls into young women and shape their feminine figures. In boys, estrogen is important in the closure of the epiphyseal plates to arrest post-pubertal growth and support bone health throughout life. It also may have beneficial actions on the male cardiovascular system.

As a systemic hormone, estrogen is important in women for the health of the skeleton, the heart, the integuments, and the brain. Women who suffer the loss of estrogen through surgery, illness, or early menopause often are advised to consider estrogen therapy to protect these organs from premature failure.

Unfortunately, estrogen replacement therapy (ERT) is a double-edged sword, with significant benefits in some organs and significant risks in others. ERT protects against vasomotor symptoms, urogenital atrophy, osteoporosis, cardiovascular disease, and perhaps Alzheimer’s disease. Unfortunately, it also increases the risk of venous thromboembolic events, recurrent myocardial infarction and cardiac death (in diseased hearts), and cancers of the uterus and breast.

Of the many diseases that impact the lives of American women, none is more feared than breast cancer, the most common cancer in females and the second leading cause of female cancer mortality. The fear of this disease causes many women to decline or discontinue ERT, a decision that can profoundly affect their long-term health. Hence, the controversy regarding ERT centers on weighing the risk-benefit balance, i.e., trying to select patients who are more likely to benefit from the hormone and less likely to suffer from its adverse effects.

Physicians—particularly gynecologists who devote their care exclusively to women’s health—have longed for the ideal estrogen that will impart all of the benefits without the risks. This ideal estrogen would relieve women of vasomotor and urogenital symptoms and prevent the dire consequences of osteoporosis, accelerated atherosclerosis, neurogenic deficit, and collagen loss from the skin, without increasing the risk of cancer and thromboembolic phenomena. Some experts believe this ideal may be found in the new class of compounds referred to as selective estrogen receptor modulators (SERMs). Although several SERMs with desirable estrogenic properties are available, none is ideal. Nevertheless, this new class of estrogenic substances—with multiple beneficial effects and fewer risks—represents an important pharmacotherapeutic advance in the care of postmenopausal women.

Tamoxifen

Tamoxifen citrate (Nolvadex; AstraZeneca, Wilmington, Del) has wide clinical applications in the treatment and prevention of breast cancer. In 1980, tamoxifen was approved by the FDA for postmenopausal women with node-positive breast cancer and for premenopausal women with estrogen-receptor (ER) positive advanced breast cancer. In 1990, the FDA extended the approval of tamoxifen to include pre- and postmenopausal women.
with node-negative, ER-positive breast cancer.

In patients with node-positive breast cancer, the 10-year-survival rate improves from 50% in control subjects to 61% in patients treated with tamoxifen for 5 years. Similar improvements in survival have been reported with tamoxifen therapy in node-negative breast cancer patients. After 5 years of tamoxifen therapy and a median follow-up of 10 years, the reduction of breast cancer recurrence and death with tamoxifen treatment compared with placebo are 47% and 26%, respectively.8

For women with ER-positive tumors (about 70% of all breast cancers), tamoxifen therapy of at least 1 year’s duration results in statistically significant recurrence and survival benefits. These results increase with the duration of treatment up to 5 years. Among ER-positive women treated with tamoxifen for 5 years—the optimal length of therapy—the annual recurrence rate is cut in half and the annual death rate is reduced by 28% (Figure 1).9 Treatment beyond 5 years does not accrue additional benefits and is associated with increased adverse events.10 Tamoxifen has little effect on animal tumors and ER-negative tumors in cell cultures and confers little or no benefit to women with ER-negative tumors.9

In ER-positive tumors, tamoxifen is believed to exert its anti-tumor effects by inhibiting the estrogen-dependent secretion of growth factors and angiogenic factors by the tumor cells, and by inducing programmed death of the tumor cells.9 An understanding of this mechanism, along with the observation that tamoxifen-treated breast cancer patients not only experience a reduction in breast cancer recurrence but also a 47% reduction in contralateral breast cancer, led to the launch of the tamoxifen chemoprevention trials in North America and Europe.

In 1992, the National Surgical Adjuvant Breast and Bowel Project (NSABP) Tamoxifen Breast Cancer Prevention Trial was launched in the United States and Canada. The results of this trial were released early because of the compelling evidence of tamoxifen's therapeutic efficacy. The drug was found to reduce the incidence of breast cancer by 44%, 51%, and 55% in women aged 35 to 49, 50 to 59, and 60 or older, respectively. Tamoxifen also was found to reduce ductal carcinoma in situ by 50%. Although tamoxifen decreased the overall occurrence of ER-positive tumors by 69%, it did not have a significant impact on the incidence of ER-negative tumors.11

Based on these results, the FDA approved the use of tamoxifen for the primary prevention of breast cancer in high-risk women. It is important to limit the use of tamoxifen to high-risk women because of the potential for serious side effects, which include endometrial cancer, pulmonary embolism, deep vein thrombosis (DVT), and cataract formation.9-11

The issue of whether tamoxifen inhibits the initial development of a tumor or suppresses an occult tumor remains unresolved. It is possible that both mechanisms are involved. This is not merely an academic concern. Questions remain as to whether a suppressed tumor may develop resistance to tamoxifen or even be stimulated by the drug, becoming more virulent during or after discontinuation of therapy. However, given the extensive data and long-term clinical experience and follow-up with tamoxifen, this scenario seems unlikely. In fact, the reduction in the incidence of breast cancer appears to continue for years after the therapy is discontinued.12,13

continued on page 57
Raloxifene

Raloxifene hydrochloride (Evista; Eli Lilly and Company, Indianapolis, Ind) was originally investigated for the treatment of breast cancer and was found to be similar to tamoxifen in its anti-tumor activity. Raloxifene was subsequently studied for its skeletal effects and was approved for osteoporosis prevention in postmenopausal women in December 1997, and for fracture prevention in 1999.

The agent mimics the effects of estrogen on the skeleton and lipids. However, it acts as a complete estrogen antagonist in the breast and the uterus, making it a more desirable SERM in the management of menopausal women with an intact uterus.

The Multiple Outcomes of Raloxifene Evaluation (MORE) trial was a randomized, placebo-controlled, multicenter study involving 7,705 postmenopausal women with osteoporosis at baseline. Although bone metabolism and fractures were the primary endpoints, many other outcomes were evaluated, including uterine and endometrial effects, bleeding, breast cancer incidence, lipid levels, clotting factors, patient tolerance, and adverse events.14-18 The results of these studies support the classification of raloxifene as a SERM with several desirable estrogen-agonistic and -antagonistic effects. Even so, it is far from perfect.

Effects on bone. In the MORE trial, both placebo- and raloxifene-treated postmenopausal women received 500 mg of supplemental calcium and 400 to 600 IU of cholecalciferol (vitamin D) daily. In these postmenopausal women with osteoporosis, a daily dose of 60 mg raloxifene increased bone mineral density (BMD) in the spine by 2.6% and in the femoral neck by 2.1% compared with placebo. The assessment of biochemical bone markers indicated that raloxifene increases BMD by decreasing bone turnover. Indeed, markers of bone resorption and formation—urinary type I collagen C-telopeptide and serum osteocalcin—were significantly decreased with raloxifene within 3 months of therapy, similar to estrogen.14,19

Raloxifene also reduced vertebral fractures in postmenopausal women with osteoporosis. Vertebral fractures occurred in 10.1% of women randomized to placebo versus 6.6% of women receiving 60 mg raloxifene daily. Although raloxifene decreased the risk of new vertebral fractures regardless of whether a spinal fracture was present at baseline, the absolute percentage decrease in the fracture rate was higher in women who did not have a fracture at baseline.14 This finding underscores the importance of diagnosing and treating osteoporosis before the development of a fracture.

One interesting observation, which is true for raloxifene and other antiresorptive agents, particularly calcitonin, is that the magnitude of the reduction in vertebral fractures is greater than would have been predicted by the modest improvement in BMD observed during therapy. This suggests that antiresorptive agents may influence bone quality, perhaps through its architectural structure, in ways that cannot be ascertained by the assessment of BMD alone. Bone quality refers to skeletal factors that strongly impact the structural properties of bone, independent of the quantity of bone, assessed by BMD. Specific factors that contribute to the structural competence of bone include its microarchitecture, degree of bone mineralization, state of the organic matrix, and rate of bone turnover. The effects
of antiresorptive agents on these factors may explain why such modest improvements in BMD—i.e., 2% to 6%—result in reductions in fracture risks in the range of 30% to 50%.

Figure 2 shows the mean changes in BMD and the corresponding reduction in vertebral fractures for the therapeutic agents currently approved for the prevention and treatment of osteoporosis. Despite significant differences in BMD increases, the reductions in vertebral fracture rates are quite comparable. In the MORE trial, there was no difference in the incidence of non-traumatic fractures at sites other than the spine, possibly because of the small number of nonvertebral fractures that occurred during the study period, which yielded insufficient power to detect a difference. A subset of patients in the MORE study is being followed for a longer time to further evaluate the incidence of nonvertebral fractures.

Effects on cardiovascular health. Raloxifene’s effects on total and low-density lipoprotein (LDL) cholesterol are similar to those of estrogen, with decreases of 11% and 6%, respectively. Unlike estrogen, which increases the circulating levels of both high-density lipoprotein (HDL) cholesterol and triglycerides, raloxifene causes an insignificant increase in HDL and a slight decrease in triglyceride levels. Serum levels of lipoprotein(a) are reduced much more with ERT (16.3%) than raloxifene therapy (4.1%), whereas fibrinogen levels are reduced more with raloxifene (12.2%) than ERT (2.8%).

The effects of raloxifene on 2 additional independent risk factors for cardiovascular disease were recently reported. Elevated levels of C-reactive protein, a circulating marker of inflammation, are associated with a significantly greater risk of myocardial infarction. Also, elevated levels of homocysteine predict a greater risk of coronary artery disease. While ERT significantly increases circulating levels of C-reactive protein (by as much as 84%), raloxifene lacks a significant effect. Like estrogen, raloxifene significantly lowers homocysteine levels by 6% to 8%.

The changes in serum levels of the several markers of cardiovascular health are summarized for both ERT and raloxifene in Table 1. Overall, raloxifene therapy is associated with favorable changes in the serum levels of several of these markers, suggesting that the SERM may substantially reduce the risk of heart disease in postmenopausal women. However, conclusive proof would require a clinical trial with cardiovascular events as the definitive endpoints. Such an investigation is currently being carried out in the Raloxifene Use for the Heart (RUTH) trial. The results should indicate whether these favorable biochemical effects are indeed associated with a reduction in the incidence of cardiovascular disease.

Effects on the endometrium. Unlike tamoxifen and toremifene (Fareston, Schering-Plough, Kenilworth, NJ), which stimulate endometrial proliferation and increase the risk of endometrial cancer, raloxifene has no stimulatory effects on either the endometrium or the myometrium. In postmenopausal women receiving raloxifene, the incidence of vaginal bleeding is the same as in women on placebo. In the MORE trial, raloxifene did not increase the risk of endometrial cancer, endometrial hyperplasia, or uterine bleeding over a follow-up period of 40 months.

Several other studies have evaluated the endometrial response to raloxifene—con-
pared with placebo or ERT—for periods ranging from 12 to 24 months. These studies have consistently reported that raloxifene has no stimulatory effects on the uterus of postmenopausal women.\textsuperscript{17,18,21} Thus, it seems clear that postmenopausal patients on raloxifene need not worry about an increased risk of polyps, endometrial proliferation, hyperplasia, or cancer. Their endometrial thickness and uterine volume will not increase, nor will they experience a greater incidence of vaginal bleeding than untreated women.\textsuperscript{5,17,18,20}

In postmenopausal women, the administration of raloxifene does not require the addition of a progestin or routine endometrial monitoring by biopsy or ultrasonography. Any bleeding during raloxifene therapy should therefore be promptly evaluated, since it is unlikely to be related to the SERM.

**Effects on the breast.** In contrast to ERT, raloxifene does not increase the frequency of breast pain or tenderness in postmenopausal women. In addition, recent data suggest that raloxifene may reduce the risk of breast cancer.

Like tamoxifen, raloxifene inhibits the growth of mammary tumors in rodents and the growth of the human MCF-7 breast cancer cell line in vitro.\textsuperscript{9,22} The latest follow-up data from the MORE trial indicate that 4 years of raloxifene therapy reduces the risk of all breast cancers by 72\% compared with placebo. At the 4-year mark of the MORE trial, a total of 79 breast cancer cases occurred—4.7 cases per 1,000 patient-years in the placebo group compared with 1.3 cases per 1,000 patient-years in the raloxifene group. The protective effect was essentially restricted to ER-positive cancers. As in previous observations, women with the highest serum estrogen levels had the highest BMD and the highest incidence of breast cancer. These same women experienced the greatest reduction in breast cancer risk with raloxifene therapy.

Because raloxifene has not yet been studied directly as a prophylactic, it cannot be recommended for the prevention of breast cancer. Several other issues regarding raloxifene and breast cancer prevention also need to be addressed. For example, the efficacy
rates of raloxifene in women at increased risk for breast cancer and in younger postmenopausal women are unknown. We also lack data regarding the optimal duration of raloxifene therapy for maximal, sustained protection against breast cancer.

These issues are expected to be resolved at the completion of the Study of Tamoxifen and Raloxifene (STAR) trial. This randomized, double-blind comparison of tamoxifen and raloxifene is the largest breast-cancer prevention study ever conducted, involving more than 300 institutions throughout the U.S., Canada, and Puerto Rico and approximately 22,000 postmenopausal women. Participants include women 35 to 59 years of age who face an increased risk of breast cancer and women 60 and older with no additional risk factors. These women are given either 20 mg tamoxifen daily or 60 mg raloxifene daily for 5 years. The study, which was launched in 1999 and is expected to continue for 5 to 10 years, should provide definitive data regarding the role of these SERMs in the prevention of breast cancer and in preventing disease in general in postmenopausal women.

**Adverse effects.** Although raloxifene exerts several desirable estrogen-agonist and -antagonist effects, it also exerts several undesirable effects (Table 2), which may preclude its administration in a large segment of postmenopausal women. Perhaps its most worrisome side effect is the increased risk of venous thromboembolic events, which has been reported to be approximately 3 times the risk incurred by women on placebo.20,22 (This level of risk is similar to that reported for estrogen use.21) Raloxifene does not improve vasomotor symptoms or vaginal dryness. Leg cramps have been reported in 6% of women on raloxifene versus 2% of women on placebo.23

Raloxifene’s effects on the central nervous system (CNS) are largely unknown and seem to differ from those of estrogen. In an in vitro system using cultured rat neurons derived from areas of the brain important for memory, raloxifene was neuroprotective at low concentrations but neurotoxic at high concentrations. Other animal studies have reported that raloxifene, like estrogen, may have a beneficial effect on cholinergic transmission within the brain and induce neurite outgrowth in ER-positive rat neuronal cell lines.12,24 Because it does not decrease the incidence of hot flushes, some experts believe that raloxifene may exert anti-estrogenic effects on the CNS. However there are few clinical studies of the effects of raloxifene on the CNS in women. The few that exist indicate neither beneficial nor adverse effects on cognition, mood, or memory.25 No clinical data on raloxifene and the risk of Alzheimer’s disease are currently available.

**Patient selection**

The candidates for tamoxifen are clearly defined. These include ER-positive breast-can-

---

**Effects of raloxifene and ERT on markers of cardiovascular disease risk in healthy postmenopausal women**

<table>
<thead>
<tr>
<th>Marker</th>
<th>Raloxifene</th>
<th>ERT</th>
</tr>
</thead>
<tbody>
<tr>
<td>LDL cholesterol</td>
<td>-12</td>
<td>-14</td>
</tr>
<tr>
<td>HDL cholesterol</td>
<td>0</td>
<td>+10</td>
</tr>
<tr>
<td>HDL2</td>
<td>+15</td>
<td>+33</td>
</tr>
<tr>
<td>Triglycerides</td>
<td>-4</td>
<td>+20</td>
</tr>
<tr>
<td>Lipoprotein(a)</td>
<td>-7</td>
<td>-19</td>
</tr>
<tr>
<td>Fibrinogen</td>
<td>-10</td>
<td>-1</td>
</tr>
<tr>
<td>Homocysteine</td>
<td>-8</td>
<td>-6.6</td>
</tr>
<tr>
<td>C-reactive protein</td>
<td>-4</td>
<td>+84.1</td>
</tr>
</tbody>
</table>

Data are reported as percent change compared with placebo except for homocysteine and C-reactive protein, which are reported as percent change from baseline.

cer patients as well as pre- and post-
menopausal women at significant risk for the
disease. There currently is no other indication
for tamoxifen therapy in the U.S. In other
countries, the drug is used—as clomiphene
citrate is in the U.S.—to induce ovulation.
Because of the risk of venous thromboem-
bolism, it is important to limit the use of
tamoxifen for the prevention of breast cancer
to women at significant risk for the disease.

The best candidates for raloxifene are not
as easily defined because several other therapeu-
tic options are available for the same indica-
tions. For example, for the prevention and
treatment of osteoporosis, options include the
bisphosphonates (alendronate and rise-
dronate), calcitonin, ERT, and raloxifene.

Consequently, to prevent or treat osteoporosis in
a postmenopausal woman with vasomotor
symptoms and/or urogenital atrophic
changes, the best option appears to be ERT,
which not only protects against bone loss but
relieves menopausal symptoms as well. A sim-
ilar woman without menopausal symptoms
who is concerned about or at risk for breast
cancer might best be treat-
ed with raloxifene, which
not only confers bone pro-
tective benefits but may diminish
breast cancer risk. How-
ever, if the same woman
has a history of venous
thromboembolism, the bis-
phosphonates or calci-
tonin might be better
options, since both ERT
and raloxifene would
expose her to an unneces-
sarily high risk of a throm-
boembolic event.

The ideal candidate for
raloxifene appears to be a
postmenopausal woman
with osteopenia or osteo-
porosis who has no
increased risk of throm-
boembolism and few or
no vasomotor symptoms.
Raloxifene would be espe-

---

### Table 2: Adverse events reported by postmenopausal women in controlled trials of raloxifene

<table>
<thead>
<tr>
<th>Adverse event</th>
<th>Raloxifene</th>
<th>Placebo</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vasomotor symptoms</td>
<td>9.7%</td>
<td>6.4%</td>
<td>.01</td>
</tr>
<tr>
<td>Leg cramps</td>
<td>7%</td>
<td>3.7%</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Influenza syndrome</td>
<td>13.4%</td>
<td>11.4%</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Peripheral edema</td>
<td>5.2%</td>
<td>4.4%</td>
<td>&lt;.01</td>
</tr>
<tr>
<td>Endometrial cavity fluid</td>
<td>8.1%</td>
<td>5.7%</td>
<td>.02</td>
</tr>
<tr>
<td>Venous thromboembolism</td>
<td>1%</td>
<td>0.3%</td>
<td>&lt;.001</td>
</tr>
</tbody>
</table>


### Table 3: Treatment options for osteoporosis: benefits and side effects

<table>
<thead>
<tr>
<th>Agent</th>
<th>Benefits</th>
<th>Side effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>ERT</td>
<td>Effective, safe, multidimensional.* Eases vasomotor and urogenital symptoms, improves mood, protects cardiovascular health</td>
<td>Bleeding, blood clots, breast cancer</td>
</tr>
<tr>
<td>Raloxifene</td>
<td>Effective, safe, multidimensional. Improves lipid profile. No bleeding or breast cancer risk</td>
<td>Blood clots. No relief of hot flushes or vaginal dryness</td>
</tr>
<tr>
<td>Alendronate, risedronate</td>
<td>Effective, safe, multidimensional</td>
<td>Difficult to take. Esophageal and gastric irritation, bleeding</td>
</tr>
<tr>
<td>Calcitonin</td>
<td>Effective, safe, unidimensional. Analgesic effects in patients with compression fractures</td>
<td>Insignificant</td>
</tr>
</tbody>
</table>

*The term “multidimensional” suggests that the agent affects more than 1 organ system.
cially suitable for such a candidate if she has experienced any bleeding on ERT or fears an increased risk of breast cancer. This would include women who have been on ERT for 5 years or more, since the use of ERT for more than 5 years significantly increases the risk of breast cancer.

In my practice, the women who are happiest with raloxifene tend to be older (4 or more years past menopause), concerned about osteoporosis and cardiovascular symptoms, and very glad to be free of vaginal bleeding while on the drug. Since the 2 most common reasons for discontinuing ERT—vaginal bleeding and the fear of breast cancer—are non-issues when raloxifene is given, compliance is likely to be high. The few cases of vaginal dryness that occur usually can be treated with lubricants, small doses of vaginal estrogen tablets, or the vaginal estrogen ring.

Conclusion

Thanks to a dramatic increase in life expectancy, American women can expect to live 30 or more years beyond the average age of menopause. With aging, the risk of health problems increases progressively. Several of these problems are specifically related to or augmented by estrogen deficiency. Despite several health benefits of ERT, its use remains very low (less than 30% in postmenopausal women) because of side effects and concerns about safety, bleeding, and breast cancer.

SERMs—particularly raloxifene—provide many of estrogen’s positive effects on bone metabolism and lipids and other markers of cardiovascular disease without increasing the risk of bleeding or breast cancer. In fact, recent data suggest that raloxifene not only fails to increase the risk of breast cancer but actually may be protective against the disease.

SERMs do not necessarily replace older therapies such as ERT, but they do enhance our ability to modify and improve therapies, individualize regimens, and boost compliance. This is especially important with long-term preventive therapy, which requires a high level of acceptance and commitment by both patient and physician. Because of their multiple beneficial effects and favorable long-term risk-benefit profile, SERMs represent an important therapeutic advance in the field of women’s health.

REFERENCES


